| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Special Articles |
Departments of Epidemiology and Biostatistics (A.V.S., D.M.B.) and Medicine (S.R.C.) and Division of Endocrinology (D.E.S.), University of California–San Francisco, San Francisco, California 94105; Section of General Internal Medicine, Minneapolis Veterans Affairs Medical Center (K.E.E.), Minneapolis, Minnesota 55417; Division of Epidemiology, University of Minnesota (K.E.E.), Minneapolis, Minnesota 55454; Department of Epidemiology (J.A.C.), University of Pittsburgh, Pittsburgh, Pennsylvania 15261; Department of Genetics and Division of Epidemiology, Department of Health Research and Policy (H.K.T.), Stanford University School of Medicine, Stanford, California 54305; and Women’s College Hospital (S.A.J.), University of Toronto, Canada M5S 1B6
Address correspondence and requests for reprints to: Ann V. Schwartz, Ph.D., University of California San Francisco, 74 New Montgomery Street, Suite 600, San Francisco, California 94105. E-mail: aschwartz{at}psg.ucsf.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Although diabetes was associated with higher bone mineral density, it was also associated with a higher risk of specific fractures. Compared with nondiabetics, women with diabetes who were not using insulin had an increased risk of hip [relative risk (RR), 1.82; 95% confidence interval (CI), 1.24–2.69] and proximal humerus (RR, 1.94; 95% CI, 1.24–3.02) fractures in multivariate models controlling for age, body mass index, bone density, and other factors associated with fractures and diabetes. Insulin-treated diabetics had more than double the risk of foot (multivariate adjusted RR, 2.66; 95% CI, 1.18–6.02) fractures compared with nondiabetics.
This study indicates that diabetes is a risk factor for hip, proximal humerus, and foot fractures among older women, suggesting that fracture prevention efforts should be a consideration in the treatment of diabetes.
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Participants attended a baseline clinic visit and returned for subsequent clinic visits approximately every 2 yr. The baseline visit was attended by 9704 women. At the second clinic visit, 8098 women attended and an additional 1021 provided questionnaire data by mail and telephone without attending the clinic. The visits included a self-administered questionnaire, questions administered by an interviewer, physical performance measures, and bone mineral density (BMD) measurement. All of the participants provided informed consent, and the protocol was approved by the institutional review boards of the participating institutions.
History of diabetes
At the baseline interview (1986–1988) participants were asked whether a doctor had ever told them that they had diabetes or "sugar" diabetes. Women who answered "yes" were also asked for their age at diagnosis, and whether they were currently using insulin. The interviewers did not obtain information on other antidiabetic medications. To limit the analyses to type 2 diabetes, those who were diagnosed before age 40 yr were excluded. This analysis included 9654 women. Fifty women were excluded: 25 women did not respond to the question regarding history of diabetes; 22 women with self-reported diabetes were younger than 40 yr old at diagnosis; and 3 women with diabetes did not report age at diagnosis.
Fracture ascertainment
Every 4 months participants were contacted by postcard or telephone to ask whether they had experienced any fractures. Women who reported a fracture were interviewed to determine its circumstances. Fractures due to major trauma such as a motor vehicle accident were excluded from these analyses. The average follow-up for nonvertebral fractures was 9.4 (±2.4) yr. In these analyses, we analyzed nonvertebral fractures as a group and also analyzed hip, proximal humerus, distal forearm, ankle, and foot fractures separately.
Reported fractures were confirmed by review of radiology reports. In some cases, the presence or absence of a fracture could not be determined. These cases were identified as "uncertain" fractures and were excluded from these analyses. The percentage of fractures that were "uncertain" varied depending on the fracture location: hip (0.0%), proximal humerus (1.9%), distal forearm (3.3%), ankle (9.9%), foot (11.4%), and all nonvertebral (13.2%) fractures. The proportion of "uncertain" cases for each fracture location considered did not differ according to history of diabetes.
Incident vertebral fractures were determined morphometrically, comparing films from baseline and the third clinic visit (1993). The criteria for an incident vertebral fracture was a change of 20% and at least 4 mm in any of the three measured heights in each vertebrae (11, 12). The average time between the vertebral x-rays was 3.7 (± 0.4) yr.
Covariates
Measurement of these variables has been described previously (8, 13, 14, 15, 16). Briefly, at baseline, a self-administered questionnaire assessed self-reported health status, physical activity (walking for exercise and average time spent on feet each day), alcohol consumption in the past year (average number of drinks per week), current cigarette smoking, medical history (history of stroke, thyroid disease, or arthritis), falls in the previous year, and family fracture history. These questions were repeated at the fourth and fifth clinic visits. The questions concerning history of stroke and falls in the previous year were repeated at all follow-up visits.
During an in-clinic interview, participants were asked about their functional status (ability to perform six instrumental activities of daily living without assistance or the use of special equipment) and their current or past use of medications (oral estrogen, thyroid hormones, seizure medications, calcium supplements, benzodiazepines, or thiazide diuretics). Dietary calcium was estimated with a validated food frequency questionnaire, developed from the Second National Health and Nutrition Examination Survey (17). Total calcium was the sum of calcium supplements and dietary calcium. A modified version of the Mini-Mental State Examination was administered to measure cognitive function (18, 19). Participants were queried at all follow-up visits regarding functional status and current use of oral estrogen and thiazide diuretics.
Height was measured using a Harpenden stadiometer (Holtain Ltd., Dyved, UK), and weight was measured with a standard balance beam scale. Grip strength was assessed using a grip dynamometer (Preston Grip dynamometer; Takei Kiki Kogyo, Tokyo, Japan.), and the results for the right and left hands were averaged. Hip abductor and triceps extensor strength were measured on the right side using a hand-held dynamometer (Sparks Instruments and Academics, Coralville, IA) (20, 21). Static balance was measured by the length of time a participant could stand (up to 10 sec) with feet in the tandem position with the eyes closed. Gait speed (m/sec) was measured as the average time to complete two trials on a standard 6-m course. The chair stand test measured how long (sec) it took a participant to stand up from a chair five times, without using her arms. Vision measures included corrected visual acuity [letter charts of Bailey and Lovie (22)], near depth perception [random dot method (23) in sec of arc], far depth perception scored as the SD of four trials [Howard-Dolman device (24)], and contrast sensitivity (25) (Vistech contrast sensitivity test system, model 6500). Measurements of height, weight, grip strength, walking speed, tandem stand, and chair stand were repeated at subsequent clinic visits.
Peripheral neuropathy
At the second clinic visit (1998–1990), lower extremity vibration sensitivity was measured using the Vibratron II (Sensortek Inc., Clifton, NJ), and pressure sensitivity was measured using the Von-Frey type esthesiometer probes. The Vibratron II measure was administered using a two-alternative forced choice procedure (16, 26). Each participant was asked to determine which of two rods was vibrating after touching each rod to a warmed great toe. The vibration intensity was decreased until the participant made five errors in a row. Vibration threshold was calculated by averaging the five lowest intensities on which the participant scored correctly and the five errors, after excluding the highest and lowest values of these ten scores (reliability, r = 0.81). A lower vibration threshold indicates better sensitivity.
Esthesiometer testing was conducted on a warmed great toe (or adjacent toe if the great toe was missing) using six filaments of increasing size (3.22–6.10, logarithm of force applied, in 0.1 g). With the eyes closed, participants were asked to identify when the examiner was touching the toe with the filament. Participants were given two chances at each level, starting with the thinnest (least stiff and hardest to feel) of the six filaments. If an incorrect response was given, then the examiner moved to the next thicker filament. The test was terminated after two correct responses at a given level; a participant’s score was equal to the size of the filament at that level (reliability, r = 0.70). The maximum (worse) score of the right and left sides was used in these analyses.
Bone densitometry
During the baseline visit, BMD was measured at the distal radius and the calcaneus (9), using single photon absorptiometry (OsteoAnalyzer; Siemens-Osteon, Wahiawa, HI). At the second clinic visit, BMD of the proximal femur (14) was measured using dual-energy x-ray absorptiometry (QDR 1000; Hologic, Inc., Waltham, MA). Measurement of bone density at the calcaneus was repeated at the fourth clinic visit.
Statistical analysis
Characteristics of the cohort are presented separately for women
who reported no history of diabetes, women with diabetes who were not
using insulin, and women with diabetes who were using insulin.
2 tests were calculated for categorical
variables, and t tests were used for continuous variables to
assess the statistical significance of differences between groups.
For nonvertebral fractures, the Cox proportional hazards model (27) was used to assess the association between diabetes and the time to first fracture after baseline. The risk of incident vertebral fracture was estimated using logistic regression models because the dates of occurrence for vertebral fractures were unknown. The SAS software (SAS Institute, Inc., Cary, NC) was used (28, 29).
Because risk factors for fracture differ depending on the fracture
location, a separate multivariate model was developed for each skeletal
site. A multivariate model for fracture site, using baseline
characteristics, was constructed with backward elimination, retaining
variables associated with fracture at P less than 0.05. The
last five variables eliminated from the backward regression model were
then each entered back into the model separately and retained if the
association with fracture was statistically significant
(P < 0.05). Variables were selected for initial entry
into the multivariate models if they had previously been found to be
associated with risk of hip (8, 30), proximal humerus
(31), distal forearm (31), ankle
(32), or foot (32) fractures in the SOF
cohort or other studies and if they were significantly associated with
diabetes (P < 0.05). The initial variables, in
addition to history of diabetes, were: age, education beyond high
school, maternal hip fracture, alcohol consumption in the past year,
calcium intake, current caffeine intake, current estrogen use, current
use of long-acting benzodiazepines, current use of thiazide diuretics,
history of stroke, self-rated health compared with others, impairments
in self-reported physical function, fell in the past year,
resting pulse, body mass index (BMI), height, height loss since age 25,
less than 4 h per day on feet, walking for exercise, grip
strength, gait speed, tandem stand eyes closed, uses arms to stand up
from chair, visual acuity, distant depth perception, near depth
perception, contrast sensitivity, and calcaneal BMD. We modeled an
interaction term for a possible interaction between diabetes and BMI
but the term was not statistically significant (P 
0.10) for any of the fracture sites.
To evaluate peripheral neuropathy, models including only those women who had vibration sensitivity and light touch discrimination measured (at visit 2) and excluding fractures before visit 2 were constructed. The association between diabetes and fracture risk in a model adjusted for peripheral neuropathy, age, BMI, and BMD was compared with the association in a model adjusted for age, BMI, and BMD.
To account for changes in performance measures and health status during the course of follow-up, proportional hazards models using time-dependent covariates were constructed with backward regression. (A model with time-dependent covariates was not developed for vertebral fractures because the date of fracture was unknown.) The variables listed above for multivariate models were also initially entered into these models. Of these, the time-dependent variables were BMI, calcaneal BMD, on feet less than 4 h per day, alcohol consumption, height, height loss since age 25, falls in previous year, oral estrogen, thiazide diuretics, history of stroke, walking for exercise, self-rated health compared with others, any difficulty with daily tasks, tandem stand, walking speed, grip strength, and ability to stand from a chair without using arms.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. As
expected, women with diabetes had poorer performance on measures of
balance and gait, peripheral neuropathy, and vision, and were more
likely to report being in fair or poor health.
|
). Even
after adjustment for BMI and age, BMD among women with diabetes was
5.2% higher at the distal radius (P < 0.001), 5.1%
higher at the calcaneus (P < 0.001), and 2.9% higher
at the femoral neck (P < 0.001) compared with
nondiabetics.
Of women without diabetes, 2426 (27.0%) had at least one nonvertebral
fracture during the average follow-up of 9.4 yr; 198 (30.1%) women
with diabetes experienced a fracture. For specific fracture sites, the
number of women who had at least one fracture during follow-up is
provided in Table 2.
|
). Among women
with diabetes who were not using insulin, this increased risk seemed to
be due to an elevated risk of hip and proximal humerus fractures. Among
women using insulin compared with nondiabetics, elevated risks were
found for proximal humerus, ankle, and foot fractures. In both groups
of women with diabetes distal forearm and incident vertebral fractures
were not elevated compared with nondiabetics. Among women with
diabetes, comparing those using insulin to those not using insulin, the
risk of foot fracture was elevated in the insulin-treated group
[age-adjusted RR, 2.54; 95% confidence interval (CI), 1.04, 6.17],
but the RRs for the other skeletal sites were not statistically
significant.
|
). Substituting distal radius or femoral
neck BMD for calcaneal BMD in these models also did not substantially
alter the associations between diabetes and fracture risk.
In models that were additionally adjusted for covariates associated
with falls, frailty, and/or bone strength, the effect estimates for the
association between diabetes and fracture risk were not substantially
altered compared with the models adjusted for age, BMI, and BMD alone
(Table 3). Results for multivariate models using time-dependent
covariates for BMI, BMD, falls, and performance measures were similar
to the multivariate models using baseline variables (results not
shown).
The associations between vibration threshold and the risk of fracture in age-adjusted models were not statistically significant. Light touch discrimination was weakly associated with nonvertebral fractures (age-adjusted RR, 1.08; 95% CI, 1.03–1.13, for 1 SD increase) but was not significantly associated with fractures at specific sites. The addition of these measures of peripheral neuropathy to models adjusted for age, BMI, and BMD did not substantially attenuate the association between diabetes and fracture risk for any of the fracture sites (results not shown).
For all fracture sites, except the proximal humerus, women with
diabetes who reported a longer time since diagnosis (14 or more years)
tended to have a higher risk of fracture, compared with nondiabetics,
than diabetics with a shorter time since diagnosis. However, this
difference was only statistically significant (P <
0.05) for hip fracture (RR, 2.40; 95% CI, 1.55–3.71, for diabetes of
>14 yr duration compared with no diabetes; RR, 1.46; 95% CI,
0.98–2.17 for diabetes of 14 or fewer years duration compared with no
diabetes). Insulin treatment is associated with a longer duration of
diabetes (Table 1), but this did not account for the association
between insulin-treated diabetes and foot fracture. In models that
adjusted for duration of diabetes as well as age, BMI, and BMD, foot
fracture risk remained elevated among insulin-treated diabetics
compared with other diabetics (RR, 2.54; 95% CI, 1.01–6.34).
The diabetics being treated with insulin may have included women with late onset type 1 diabetes (33, 34). Because women with type 1 diabetes tend to have a lower BMI (1), we excluded the 59 (56% of 106) insulin-treated diabetics who had a BMI less than 30 kg/m2 (definition of obesity (35)). Women with insulin-treated diabetes who were obese (and, therefore, more likely to have type 2 diabetes) continued to have a higher risk of foot fracture compared with nondiabetic women in a model adjusted for age, BMI, and BMD (RR, 5.16; 2.07–12.9).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Diabetes is not generally considered a risk factor for fracture, but
some previous studies have found an association. Studies in Norway
identified diabetes as a risk factor for hip fracture in middle-aged
(35–49 yr old; Ref. 7) and older (50 yr old) women
(6). Previous reports from the SOF cohort, based on a
smaller set of fractures, found an increased risk of foot fracture
(32) and proximal humerus fracture (31) among
insulin-treated diabetics and an increased, but not statistically
significant, risk of hip fracture among noninsulin-treated diabetics
(8). Heath et al. (3), evaluating
records from the Mayo Clinic, reported that the risk of ankle fractures
was elevated among women with diabetes but did not find a higher risk
for other fracture sites. These results, however, were not adjusted for
body size or BMD.
Other studies have found no increase in the risk of fracture among women with diabetes. Melchior et al. (4) found no differences in hip and Colles’ fracture rates for women with diabetes who were being treated with insulin compared with nondiabetic women. The Rotterdam Study found a lower risk of nonspine fracture among women with diabetes (5). The disparity between these results and our findings may be due to differences in the ages of the women in the two studies and the lower proportion of distal forearm fractures in the SOF cohort. The women in the Rotterdam Study were 50 yr or older at the time of fracture and had a preponderance of wrist and forearm fractures (60% of nonspine fractures), whereas in the SOF only 23% of all nonspine fractures were of the distal forearm. In the SOF we found no association between diabetes and risk of distal forearm fracture.
In this study, women with diabetes had a greater risk of fracture despite having higher BMD than women without diabetes. One possible explanation is that the comorbidities associated with diabetes increase the risk of fracture. Another possibility is that diabetes is associated with a decrease in bone strength that is not reflected in the measurement of BMD.
We considered a range of risk factors for fracture that are also associated with diabetes, including falls, poor vision, less exercise, limitations in functional ability, and use of long-acting benzodiazepines, in an effort to identify baseline variables contributing to the higher risk of fracture among women with diabetes. Such factors accounted for only a small portion of the association between diabetes and fracture risk in our models.
For foot fracture, in particular, we had hypothesized that peripheral neuropathy might account for the association with diabetes. Previous studies among patients with diabetes have found that peripheral neuropathy is associated with metatarsal fractures (36) and calcaneal fractures (37). However, the two measures of neuropathy available to us, vibration sensitivity and light touch discrimination, did not substantially alter the association between diabetes and foot fracture in our models. A more sensitive measure of peripheral neuropathy, such as nerve conduction velocity, was not available (38).
One possible reason that the available measures accounted for only a small portion of the association between diabetes and fracture is that these models included only measurements at baseline (or, in the case of peripheral neuropathy, at the second visit). The mean follow-up for nonspine fractures was over 9 yr. Because women with diabetes experienced a more rapid decline in several measures of health, we hypothesized that measurements obtained closer to the date of fracture might account for a larger portion of the association between diabetes and fracture. However, using time-dependent covariates for falls, balance, strength, functional ability, bone density, and other risk factors for fracture in the multivariate models did not substantially alter the associations between diabetes and fracture compared with models with baseline variables only. It is also possible that there are risk factors that were not measured in the SOF, such as decreased renal function or retinopathy, or that were not adequately captured in the measures available in the SOF. For example, vision was only measured at baseline and may have changed more rapidly for women with diabetes.
We considered insulin treatment as one marker of severity of diabetes. There was a tendency for the fracture risk among insulin-treated diabetics to be higher for all of the fracture sites considered, except the hip, but the difference was only statistically significant for foot fracture.
Duration of diabetes also seemed to be associated with a higher risk of fracture although results were only statistically significant for hip fracture. Insulin treatment was associated with a longer duration of diabetes in our data, but duration of diabetes did not account for the association between insulin treatment and foot fracture among diabetics. A measure of glycemic control was not available on the full cohort of participants in the SOF, so we could not explore the effect of glycemic control on fracture risk.
Other limitations of this study should be noted. Because diabetes was determined by self-report, those participants identified as not having diabetes probably included some women with undiagnosed diabetes. However, this misclassification would tend to weaken any association between diabetes and fracture. In addition, some women with late onset type 1 diabetes may have been included in our group of women with diabetes. Another limitation was the relatively small number of women with diabetes who were using insulin. Study participants were volunteers, community-dwelling, ambulatory, and mainly white. Results may not apply to the broader population of older women, especially those in institutions.
These results indicate that diabetes should be considered as a risk factor for particular types of fractures. Despite having a higher bone density, on average, the women with diabetes in our study had a higher risk of hip and proximal humerus fractures. Treatment with insulin was associated with an increased risk of foot fracture. Other factors associated with frailty or fracture, including falls, did not account for the association between diabetes and fracture.
This study underscores the need for a more aggressive focus on identifying and addressing risk factors for fracture in women with diabetes. Research is needed into the efficacy of current treatments to improve bone strength among women with diabetes. Further study of the extent to which the association between diabetes and fracture risk is mediated by complications of diabetes or by an increase in falls would be useful in guiding fracture prevention efforts.
|
Acknowledgments |
|---|
University of Maryland: M. Hochberg (principal investigator), R. Sherwin (co-investigator), J. Lewis (project director), D. Wright (clinic coordinator), A. Bauer, C. Boehm, G. Cullum, L. Finazzo, M. E. Flaks, T. Ford, D. Harris, B. Hohman, T. Page, J. Schlossberg, C. Shaffer, A. Trimble, and S. Trusty.
University of Minnesota: K. Ensrud (principal investigator), P. Schreiner (co-investigator), K. Margolis (co-investigator), C. Bell (project director), E. Mitson (clinic coordinator), C. Bird, D. Blanks, J. Griffith, F. Imker-Witte, K. Jacobson, K. Kiel, K. Knauth, M. Neely, N. Nelson, E. Penland-Miller, M. Riley-Alves, and G. Saecker.
University of Pittsburgh: J. A. Cauley (principal investigator), L. H. Kuller (co-principal investigator), M. Vogt (co-investigator), L. Harper (project director), L. Buck (clinic coordinator), C. Bashada, D. Cusick, G. Engleka, A. Flaugh, A. Githens, M. Gorecki, K. McCune, D. Medve, M. Nasim, C. Newman, S. Rudovsky, and N. Watson.
The Kaiser Permanente Center for Health Research (Portland, OR): E. Harris (principal investigator, project director), W. M. Vollmer (co-investigator), E. Orwoll (co-investigator), H. Nelson (co-investigator), Marge Erwin (project administrator, clinic coordinator), J. Cogswell, A. Doherty, D. Franco, R. Garza, J. Kann, M. Klein, L. Loter, K. Redden, C. Romero, K. Snider, and J. Wallace.
Received April 21, 2000.
Revised August 8, 2000.
Accepted September 11, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  A. V. Schwartz, P. Garnero, T. A. Hillier, D. E. Sellmeyer, E. S. Strotmeyer, K. R. Feingold, H. E. Resnick, F. A. Tylavsky, D. M. Black, S. R. Cummings, et al. Pentosidine and Increased Fracture Risk in Older Adults with Type 2 Diabetes J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2380 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, and T. Sugimoto Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus Eur. J. Endocrinol., February 1, 2009; 160(2): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Loke MBBS MD, S. Singh MD MPH, and C. D. Furberg MD PhD Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis Can. Med. Assoc. J., January 6, 2009; 180(1): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Fernandez-Real, M. Izquierdo, F. Ortega, E. Gorostiaga, J. Gomez-Ambrosi, J. M. Moreno-Navarrete, G. Fruhbeck, C. Martinez, F. Idoate, J. Salvador, et al. The Relationship of Serum Osteocalcin Concentration to Insulin Secretion, Sensitivity, and Disposal with Hypocaloric Diet and Resistance Training J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 237 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D Prisby, J. M Swift, S. A Bloomfield, H. A Hogan, and M. D Delp Altered bone mass, geometry and mechanical properties during the development and progression of type 2 diabetes in the Zucker diabetic fatty rat J. Endocrinol., December 1, 2008; 199(3): 379 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Michaelsson, L. Lind, J. Frystyk, A. Flyvbjerg, R. Gedeborg, C. Berne, B. Zethelius, H. Mallmin, S. Soderberg, and H. Melhus Serum Adiponectin in Elderly Men Does Not Correlate with Fracture Risk J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4041 - 4047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Tao, J.-M. Liu, H.-Y. Zhao, L.-H. Sun, W.-Q. Wang, X.-Y. Li, and G. Ning Differences between Measurements of Bone Mineral Densities by Quantitative Ultrasound and Dual-Energy X-Ray Absorptiometry in Type 2 Diabetic Postmenopausal Women J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1670 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kahn, B. Zinman, J. M. Lachin, S. M. Haffner, W. H. Herman, R. R. Holman, B. G. Kravitz, D. Yu, M. A. Heise, R. P. Aftring, et al. Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care, May 1, 2008; 31(5): 845 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Cauley and K. E. Ensrud Considering Competing Risks . . . Not All Black and White Arch Intern Med, April 28, 2008; 168(8): 793 - 795. [Full Text] [PDF]
|
|
|
|
|
|
C. Meier, M. E. Kraenzlin, M. Bodmer, S. S. Jick, H. Jick, and C. R. Meier Use of Thiazolidinediones and Fracture Risk Arch Intern Med, April 28, 2008; 168(8): 820 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Holmberg, P. M. Nilsson, J-A. Nilsson, and K. Akesson The Association between Hyperglycemia and Fracture Risk in Middle Age. A Prospective, Population-Based Study of 22,444 Men and 10,902 Women J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamamoto, T. Yamaguchi, M. Yamauchi, S. Yano, and T. Sugimoto Serum Pentosidine Levels Are Positively Associated with the Presence of Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1013 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Monami, B. Cresci, A. Colombini, L. Pala, D. Balzi, F. Gori, V. Chiasserini, N. Marchionni, C. M. Rotella, and E. Mannucci Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients: A case-control study Diabetes Care, February 1, 2008; 31(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-F. Chen, C.-A. Ho, and C.-Y. Li Increased Risks of Hip Fracture in Diabetic Patients of Taiwan: A population-based study Diabetes Care, January 1, 2008; 31(1): 75 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E Murphy and P. T Rodgers Effects of Thiazolidinediones on Bone Loss and Fracture Ann. Pharmacother., December 1, 2007; 41(12): 2014 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mascitelli MD and F. Pezzetta MD Diabetes and osteoporotic fractures Can. Med. Assoc. J., November 20, 2007; 177(11): 1391 - 1392. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Manolagas and M. Almeida Gone with the Wnts: {beta}-Catenin, T-Cell Factor, Forkhead Box O, and Oxidative Stress in Age-Dependent Diseases of Bone, Lipid, and Glucose Metabolism Mol. Endocrinol., November 1, 2007; 21(11): 2605 - 2614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Janghorbani, R. M. Van Dam, W. C. Willett, and F. B. Hu Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture Am. J. Epidemiol., September 1, 2007; 166(5): 495 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sugiyama, T. Takaki, K. Sakanaka, H. Sadamaru, K. Mori, Y. Kato, T. Taguchi, and T. Saito Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli J. Endocrinol., July 1, 2007; 194(1): 213 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Schwartz and D. E. Sellmeyer Thiazolidinedione Therapy Gets Complicated: Is bone loss the price of improved insulin resistance? Diabetes Care, June 1, 2007; 30(6): 1670 - 1671. [Full Text] [PDF]
|
|
|
|
|
|
S. Yaturu, B. Bryant, and S. K. Jain Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men Diabetes Care, June 1, 2007; 30(6): 1574 - 1576. [Full Text] [PDF]
|
|
|
|
|
|
L. L. Lipscombe, S. A. Jamal, G. L. Booth, and G. A. Hawker The Risk of Hip Fractures in Older Individuals With Diabetes: A population-based study Diabetes Care, April 1, 2007; 30(4): 835 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Watts and D. A. D'Alessio Type 2 diabetes, thiazolidinediones: bad to the bone? J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3276 - 3278. [Full Text] [PDF]
|
|
|
|
|
|
A. V. Schwartz, D. E. Sellmeyer, E. Vittinghoff, L. Palermo, B. Lecka-Czernik, K. R. Feingold, E. S. Strotmeyer, H. E. Resnick, L. Carbone, B. A. Beamer, et al. Thiazolidinedione Use and Bone Loss in Older Diabetic Adults J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3349 - 3354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Bonds, J. C. Larson, A. V. Schwartz, E. S. Strotmeyer, J. Robbins, B. L. Rodriguez, K. C. Johnson, and K. L. Margolis Risk of Fracture in Women with Type 2 Diabetes: the Women's Health Initiative Observational Study J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3404 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Munshi, L. Grande, M. Hayes, D. Ayres, E. Suhl, R. Capelson, S. Lin, W. Milberg, and K. Weinger Cognitive Dysfunction Is Associated With Poor Diabetes Control in Older Adults Diabetes Care, August 1, 2006; 29(8): 1794 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Janghorbani, D. Feskanich, W. C. Willett, and F. Hu Prospective Study of Diabetes and Risk of Hip Fracture: The Nurses' Health Study Diabetes Care, July 1, 2006; 29(7): 1573 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Strotmeyer, A. V. Schwartz, and A. B. Newman Thiazolidinediones and the risk of nontraumatic fractures in patients with diabetes: in reply. Arch Intern Med, May 8, 2006; 166(9): 1043 - 1043. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Durso Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA, April 26, 2006; 295(16): 1935 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Quandt, J. M. Stafford, R. A. Bell, S. L. Smith, B. M. Snively, and T. A. Arcury Predictors of falls in a multiethnic population of older rural adults with diabetes. J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2006; 61(4): 394 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Volpato, S. G. Leveille, C. Blaum, L. P. Fried, and J. M. Guralnik Risk Factors for Falls in Older Disabled Women With Diabetes: The Women's Health and Aging Study J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2005; 60(12): 1539 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Thrailkill, C. K. Lumpkin Jr., R. C. Bunn, S. F. Kemp, and J. L. Fowlkes Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E735 - E745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Botolin, M.-C. Faugere, H. Malluche, M. Orth, R. Meyer, and L. R. McCabe Increased Bone Adiposity and Peroxisomal Proliferator-Activated Receptor-{gamma}2 Expression in Type I Diabetic Mice Endocrinology, August 1, 2005; 146(8): 3622 - 3631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Strotmeyer, J. A. Cauley, A. V. Schwartz, M. C. Nevitt, H. E. Resnick, D. C. Bauer, F. A. Tylavsky, N. de Rekeneire, T. B. Harris, and A. B. Newman Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black Adults: The Health, Aging, and Body Composition Study Arch Intern Med, July 25, 2005; 165(14): 1612 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D J Hadjidakis, A M Mylonakis, M E Sfakianakis, A E Raptis, and S A Raptis Diabetes and premature menopause: is their co-existence detrimental to the skeleton? Eur. J. Endocrinol., March 1, 2005; 152(3): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kemmis and D. Stuber Diabetes and Osteoporotic Fractures: The Role of the Diabetes Educator The Diabetes Educator, March 1, 2005; 31(2): 187 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Kern, N. R. Powe, M. A. Levine, A. L. Fitzpatrick, T. B. Harris, J. Robbins, and L. P. Fried Association between Screening for Osteoporosis and the Incidence of Hip Fracture Ann Intern Med, February 1, 2005; 142(3): 173 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J Sinclair Diabetes mellitus in senior citizens -- a major threat to personal independence The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 3 - 5. [PDF]
|
|
|
|
|
|
W. D. Leslie, S. Derksen, C. Metge, L. M. Lix, E. A. Salamon, P. Wood Steiman, and L. L. Roos Fracture risk among First Nations people: a retrospective matched cohort study Can. Med. Assoc. J., October 12, 2004; 171(8): 869 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Chu, J. L. Kelsey, T. H. M. Keegan, B. Sternfeld, M. Prill, C. P. Quesenberry, and S. Sidney Risk Factors for Proximal Humerus Fracture Am. J. Epidemiol., August 15, 2004; 160(4): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H.M. Keegan, A. V. Schwartz, D. C. Bauer, D. E. Sellmeyer, and J. L. Kelsey Effect of Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Type 2 Diabetic Women: The Fracture Intervention Trial Diabetes Care, July 1, 2004; 27(7): 1547 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Brown and J. L. Sharpless Osteoporosis: An Under-appreciated Complication of Diabetes Clin. Diabetes, January 1, 2004; 22(1): 10 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Diabetes Issues in Women and Children: Polycystic ovary syndrome Diabetes Care, August 1, 2003; 26(8): 2457 - 2463. [Full Text] [PDF]
|
|
|
|
|
|
E. W. Gregg and A. Brown Cognitive and Physical Disabilities and Aging-Related Complications of Diabetes Clin. Diabetes, July 1, 2003; 21(3): 113 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Hasselman, M. T. Vogt, K. L. Stone, J. A. Cauley, and S. F. Conti Foot and Ankle Fractures in Elderly White Women: Incidence and Risk Factors J. Bone Joint Surg. Am., May 1, 2003; 85(5): 820 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W Gregg, M. M Engelgau, and V. Narayan Complications of diabetes in elderly people BMJ, October 26, 2002; 325(7370): 916 - 917. [Full Text] [PDF]
|
|
|
|
|
|
J. N Basile Systolic blood pressure BMJ, October 26, 2002; 325(7370): 917 - 918. [Full Text] [PDF]
|
|
|
|
|
|
K. J. Ottenbacher, G. V. Ostir, M. K. Peek, J. S. Goodwin, and K. S. Markides Diabetes Mellitus as a Risk Factor for Hip Fracture in Mexican American Older Adults J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2002; 57(10): M648 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Schwartz, T. A. Hillier, D. E. Sellmeyer, H. E. Resnick, E. Gregg, K. E. Ensrud, P. J. Schreiner, K. L. Margolis, J. A. Cauley, M. C. Nevitt, et al. Older Women With Diabetes Have a Higher Risk of Falls: A prospective study Diabetes Care, October 1, 2002; 25(10): 1749 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Chau and S. V. Edelman Osteoporosis and Diabetes Clin. Diabetes, July 1, 2002; 20(3): 153 - 157. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud Genetics of Osteoporosis Endocr. Rev., June 1, 2002; 23(3): 303 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Franz, J. P. Bantle, C. A. Beebe, J. D. Brunzell, J.-L. Chiasson, A. Garg, L. A. Holzmeister, B. Hoogwerf, E. Mayer-Davis, A. D. Mooradian, et al. Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications Diabetes Care, January 1, 2002; 25(1): 148 - 198. [Full Text] [PDF]
|
|
|
|
|
|
D. Chau and S. V. Edelman Clinical Management of Diabetes in the Elderly Clin. Diabetes, October 1, 2001; 19(4): 172 - 175. [Full Text] [PDF]
|
|
|
|
|
|
G. Isaia, R. Giorgino, and S. Adami High Prevalence of Hypovitaminosis D in Female Type 2 Diabetic Population Diabetes Care, August 1, 2001; 24(8): 1496 - 1496. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Nicodemus and A. R. Folsom Type 1 and Type 2 Diabetes and Incident Hip Fractures in Postmenopausal Women Diabetes Care, July 1, 2001; 24(7): 1192 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Nelson and S. J. Jacober Why Do Older Women with Diabetes Have an Increased Fracture Risk? J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 29 - 31. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
